RT Journal Article
T1 Incremental effect for antisocial personality disorder genetic risk combining 5-HTTLPR and 5-HTTVNTR polymorphisms
A1 García, Luis F.
A1 Aluja, Antón
A1 Fibla, Joan
A1 Cuevas Esteban, Lara
A1 García, Óscar
AB As the serotonin transporter gene (SLC6A4 or 5-HTT) is a key regulator of central serotonergic activity, several association studies between Antisocial Personality Disorder (APD) and the SLC6A4 polymorphisms have been conducted in the last decade. In the present study, the role of both 5-HTTLPR and 5-HTTVNTR polymorphisms of the SLC6A4 gene in APD is investigated. A sample of 147 male inmates was analyzed. APD was assessed by Aluja's Antisocial Personality Disorder Scale, a measure that correlates 0.73 with the dimensional score of DSM-IV APD and 0.62 with factor II of the Psychopathy Checklist-Revised. Inmates presenting both 5-HTTLPR S/S + S/L and 5-HTTVNTR 12/12 had a higher risk of being classified in the APD group (Odds ratio = 3.48). The results also showed that the genotype and haplotype distribution was more dissimilar when extreme groups were compared with odds ratios up to 6.50. Our results supported that, in addition to the widely investigated 5-HTTLPR polymorphism, the 5-HTTVNTR polymorphism might be an interesting candidate for association studies with APD. Results also suggested that previous failures to replicate the association between serotonin transporter gene polymorphisms and APD, or similar phenotypes, could have been due to an under-representation of extremely high APD subjects in the samples analyzed.
PB Elsevier
SN 0165-1781
YR 2010
FD 2010-05-15
LK https://hdl.handle.net/20.500.14352/132673
UL https://hdl.handle.net/20.500.14352/132673
LA eng
NO Garcia, L. F., Aluja, A., Fibla, J., Cuevas, L., & García, O. (2010). Incremental effect for antisocial personality disorder genetic risk combining 5-HTTLPR and 5-HTTVNTR polymorphisms. Psychiatry Research, 177(1-2), 161-166. https://doi.org/10.1016/j.psychres.2008.12.018
NO Ministerio de Educación y Ciencia (España)
NO Universidad de Lleida
NO Generalitat de Catalunya
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 31 mar 2026